| Literature DB >> 28214872 |
Yun Xu, Lujun Chen, Bin Xu, Yuqi Xiong, Min Yang, Xiaohui Rui, Liangrong Shi, Changping Wu, Jingting Jiang, Binfeng Lu.
Abstract
BACKGROUND/AIMS: T-bet, a member of the T-box family of transcription factors, is a key marker of type I immune response within the tumor microenvironment, and has been previously reported by us to serve as an important prognostic indicator for human gastric cancer patients and a potential biomarker for immunotherapy. In the present study, we aimed to assess the clinical significance and prognostic value of T-bet+ tumor-infiltrating lymphocytes in human epithelial ovarian cancer.Entities:
Keywords: Epithelial ovarian cancer; T-bet+; Tumor-infiltrating lymphocytes
Mesh:
Substances:
Year: 2017 PMID: 28214872 PMCID: PMC9393827 DOI: 10.1159/000456600
Source DB: PubMed Journal: Cell Physiol Biochem ISSN: 1015-8987
Association between clinicopathological characteristics and the expression of T-bet+ TILs in tumor nest. Values in bold signify P<0.05
| Characteristics | Density of T-bet+ TILs in tumor nest | ||||||
|---|---|---|---|---|---|---|---|
| Low | High | χ |
| ||||
| Cases | % | Cases | % | ||||
| Age (years) | < 50 | 18 | 69.23 | 8 | 30.77 | 0.878 | 0.645 |
| 50–60 | 24 | 80.00 | 6 | 20.00 | |||
| ≥60 | 19 | 76.00 | 6 | 24.00 | |||
| Pathological type | Serous adenocarcinoma | 44 | 81.48 | 10 | 18.52 | 3.32 | 0.068 |
| Others | 17 | 62.96 | 10 | 37.04 | |||
| FIGO stage | I-11 | 9 | 56.25 | 7 | 43.75 | 3.606 | 0.058 |
| III-IV | 50 | 79.37 | 13 | 20.63 | |||
| Tumor site | Unilateral | 27 | 67.50 | 13 | 32.50 | 2.953 | 0.086 |
| Bilateral | 32 | 84.21 | 6 | 15.79 | |||
| Tumor size | < 8cm | 19 | 82.61 | 4 | 17.39 | 0.859 | 0.354 |
| ≥ 8cm | 40 | 72.73 | 15 | 27.27 | |||
| CA125 level | ≤ 35 | 1 | 25.00 | 3 | 75.00 | 5.387 | 0.020 |
| > 35 | 57 | 77.03 | 17 | 22.97 | |||
| Distant metastasis | No | 3 | 42.86 | 4 | 57.14 | 4.115 | 0.043 |
| Yes | 56 | 77.78 | 16 | 22.22 | |||
Fig. 1Positive T-bet immunostaining in the cell nuclei of the infiltrating immune cells in ovarian cancer as well as benign ovarian cyst tissues.
Fig. 2Analysis of the peripheral blood displayed the percentages of T-bet+CD4+ T cells, T-bet+CD8+ T cells and T-bet+ NK cells as 32.0%, 50.8% and 94.9% respectively. Analysis of T-bet+CD4+ T cells, T-bet+CD8+ T cells and T-bet+ NK cells in the tumor tissue showed the percentage as 15.1%, 16.8% and 16.5%, respectively. NK cells were the largest group of cells among T-bet+ TILs.
Association between clinicopathological characteristics and the expression of T-bet+ TILs in tumor stroma
| T-bet+ TILs in tumor stroma | |||||||
|---|---|---|---|---|---|---|---|
| Characteristics | Low | High | χ |
| |||
| Cases | % | Cases | % | ||||
| Age (years) | < 50 | 3 | 11.54 | 23 | 88.46 | 0.74 | 0.691 |
| 50–60 | 6 | 20.00 | 24 | 80.00 | |||
| ≥ 60 | 4 | 16.00 | 21 | 84.00 | |||
| Pathological type | Serous adenocarcinoma | 11 | 20.37 | 43 | 79.63 | 2.245 | 0.134 |
| Others | 2 | 7.41 | 25 | 92.59 | |||
| FIGO stage | I-II | 1 | 6.25 | 15 | 93.75 | 1.52 | 0.218 |
| III-IV | 12 | 19.05 | 51 | 80.95 | |||
| Tumor site | Unilateral | 6 | 15.00 | 34 | 85.00 | 0.164 | 0.685 |
| Bilateral | 7 | 18.42 | 31 | 81.58 | |||
| Tumor size | <8cm | 4 | 17.39 | 19 | 82.61 | 0.012 | 0.912 |
| ≥8cm | 9 | 16.36 | 46 | 83.64 | |||
| CA125 level | ≤35 | 0 | 0.00 | 4 | 100.00 | 0.843 | 0.358 |
| >35 | 13 | 17.57 | 61 | 82.43 | |||
| Distant metastasis | No | 0 | 0.00 | 7 | 100.00 | 1.513 | 0.219 |
| Yes | 13 | 18.06 | 59 | 81.94 | |||
Fig. 3The average OS times of patients with high or low expression of T-bet+ TILs in tumor nest were 71.4 and 49.8 months, respectively (P = 0.009), and in tumor stroma were 61.9 and 32.5 months, respectively (P = 0.015).
Cox's proportional hazards model analysis of the density of infiltrating T-bet+ TILs in tumor nest. Values in bold signify P<0.05
| Characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age (years) | ||||||
| 50–60/<50 | 1.275 | 0.559–2.909 | 0.564 | 1.474 | 0.613–3.543 | 0.386 |
| ≥60/<50 | 2.998 | 1.358–6.622 | 0.007 | 2.451 | 1.023–5.872 | 0.044 |
| Pathological type | ||||||
| Serous adenocarcinoma/others | 1.035 | 0.533–2.011 | 0.92 | 1.537 | 0.729–3.24 | 0.259 |
| FIGO stage | ||||||
| III-IV/I-II | 7.505 | 1.791–31.440 | 0.006 | 6.659 | 1.477–30.02 | 0.014 |
| Tumor site | ||||||
| Bilateral/unilateral | 1.110 | 0.605–2.038 | 0.736 | 0.506 | 0.251–1.019 | 0.056 |
| Tumor size (cm) | ||||||
| ge;8/<8 | 0.582 | 0.302–1.122 | 0.106 | 0.798 | 0.385–1.652 | 0.543 |
| T-bet+ TILs in tumor nest | ||||||
| High/low | 0.276 | 0.098–0.780 | 0.015 | 0.235 | 0.07–0.795 | 0.020 |
Cox's proportional hazards model analysis of the density of infiltrating T-bet+ TILs in tumor stroma. Values in bold signify P<0.05
| Characteristics | HR | Univariate 95% CI |
| HR | Multivariate 95% CI |
|
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| 50–60/< 50 | 1.275 | 0.559–2.909 | 0.564 | 1.316 | 0.531–3.259 | 0.553 |
| ≥60/<50 | 2.998 | 1.358–6.622 | 0.007 | 2.264 | 0.929–5.517 | 0.072 |
| Pathological type | ||||||
| Serous adenocarcinoma/others | 1.035 | 0.533–2.011 | 0.92 | 1.224 | 0.589–2.544 | 0.588 |
| FIGO stage | ||||||
| III-IV/I-II | 7.505 | 1.791–31.440 | 0.006 | 6.834 | 1.552–30.082 | 0.011 |
| Tumor site | ||||||
| Bilateral/unilateral | 1.110 | 0.605–2.038 | 0.736 | 0.554 | 0.274–1.12 | 0.100 |
| Tumor size | ||||||
| ≥8/<8 | 0.582 | 0.302–1.122 | 0.106 | 0.651 | 0.316–1.341 | 0.244 |
| T-bet+ TILs in tumor stroma | ||||||
| High/low | 0.418 | 0.202–0.866 | 0.019 | 0.497 | 0.229–1.078 | 0.077 |
Cox's proportional hazards model analysis of the density of infiltrating T-bet+ TILs in tumor nest and stroma. Values in bold signify P<0.05. #: Total patients were divided into 3 groups. Patients with the low density of infiltrating T-bet+ lymphocytes both in tumor nest and stroma were considered as group 1, named “Both Low”. Patients with the high density of infiltrating T-bet+ lymphocytes only in tumor stroma were considered as group 2, named “Stroma High” (For there was no patient with the density of infiltrating T-bet+ lymphocytes only high in tumor nest in this study), and both high in tumor nest and stroma were considered as group 3, named “Both High”
| Clinical parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age(year) | ||||||
| 50–60/<50 | 1.275 | 0.559–2.909 | 0.564 | 1.183 | 0.462–3.031 | 0.762 |
| ≥60/<50 | 2.998 | 1.358–6.622 | 0.007 | 2.417 | 0.989–5.906 | 0.053 |
| Pathological type | ||||||
| Serous adenocarcinoma/Others | 1.035 | 0.533–2.011 | 0.92 | 1.482 | 0.690–3.186 | 0.313 |
| Figo Stage | ||||||
| III-IV/I-I1 | 7.505 | 1.791–31.440 | 0.006 | 5.637 | 1.243–25.564 | 0.025 |
| Location | ||||||
| Bilateral/Unilateral | 1.110 | 0.605–2.038 | 0.736 | 0.546 | 0.266–1.119 | 0.098 |
| Tumor size(cm) | ||||||
| ≥8/<8 | 0.582 | 0.302–1.122 | 0.106 | 1.269 | 0.602–2.678 | 0.532 |
| T-bet+TILs in tumor nest and stroma# | ||||||
| Stroma High/ Both Low | 0.540 | 0.256–1.143 | 0.107 | 0.636 | 0.284–1.427 | 0.272 |
| Both High/ Both Low | 0.180 | 0.056–0.577 | 0.004 | 0.180 | 0.047–0.694 | 0.013 |